DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

DIA - The DIA Obesity Consortium
At a Glance
Launch Year
2025
Current Phase
Phase II (July 2026 to December 2027)
Members
60+ experts across 11 organizations
Working Groups
01 Standardizing Label-Enabling Efficacy Endpoints
02 Designing Clinical Trials for Multiple Indications
Project Lead
Maria Vassileva
DIA
Project Manager
Sorcha McCrohan
DIA
Overview

A Multi-Stakeholder Partnership for Better Obesity Trials

The DIA Obesity Consortium is a multi-stakeholder public-private partnership dedicated to improving the efficiency and impact of obesity clinical trials. Building on a shared commitment to advancing clinically meaningful outcomes, the consortium works to standardize endpoints, optimize trial design, and explore innovative approaches that may address multiple indications within a single development program.

Now in Phase II, the consortium brings together more than 60 experts from 11 organizations to turn the alignment reached with FDA and EMA in Phase I into practical resources for endpoint measurement and multi-indication trial design.

Through structured dialogue and collaboration among regulators, industry leaders, academic and nonprofit experts, payers, and patients, the consortium defines and maps the optimal path forward for the field—accelerating scientific progress while maintaining rigor and relevance.

Why It Matters

Addressing Critical Gaps in Obesity Clinical Development

This work benefits the life sciences community by building consensus around standardized, fit-for-purpose clinical measures and endpoints that will reduce development inefficiencies, strengthen regulatory review, and accelerate patient access to safe, effective obesity therapies worldwide.

Standardizing Fragmented Endpoints

Addressing fragmentation and variability in obesity clinical trial design, endpoints, and outcome measures that limit comparability and regulatory confidence.

More Rigorous, Patient-Relevant Trials

Supporting more efficient, scientifically rigorous, and patient-relevant trials that better inform regulatory and clinical decision-making.

Multi-Stakeholder Alignment

Advancing collaboration among regulators, industry, academic researchers, nonprofits, and patients to align on what constitutes clinically meaningful benefit in obesity.

How We Work

Working Groups

Two focused working groups deliver coordinated outputs to improve Phase 3 obesity trial design and endpoint standardization.

01
Standardizing Label-Enabling Efficacy Endpoints

Focused on building consensus around what, how, and when to measure label-enabling efficacy endpoints in Phase 3 obesity trials, with particular attention to body composition, physical function, and muscle preservation as indicators of meaningful weight loss.

02
Designing Clinical Trials for Multiple Indications

Centered on identifying efficient clinical trial designs to support multiple obesity-related indications, including prioritization of key comorbidities, use of multi-endpoint or single-trial approaches, and evaluation of surrogate endpoints to reduce reliance on standalone outcome studies.

Progress & Milestones

Key Activities and Status

From stakeholder formation to published consensus, a structured pathway from expert insight to measurable global impact.

2025
Pre-Consortium Engagement and Foundation Building

Initial stakeholder engagement to assess alignment, define priorities, and establish the strategic framework for the DIA Obesity Consortium.

Q2 2025
Executive Roundtable and Global Presentation

Convened an Executive Roundtable on April 24, 2025 in Gaithersburg, MD with FDA participation, followed by a presentation of key themes at the DIA 2025 Global Annual Meeting on June 18, 2025 in Washington, DC. Insights were published in the September 2026 issue of Global Forum: Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation.

Sept 2025 – May 2026
Phase I: Core Endpoint Consensus Development

Launched the consortium with 10 member companies and two working groups to build consensus on clinically meaningful endpoints and multi-indication trial design. Included the DIA European Executive Roundtable on Obesity Drug Development, held with EMA participation on March 23, 2026 in Rotterdam.

June 2026
DIA 2026 Global Annual Meeting

Presented Phase I outcomes at the DIA 2026 Global Annual Meeting on June 16, 2026 in Philadelphia, PA.

Sept – Oct 2026
Executive Roundtable Insights Published

Published back-to-back Executive Roundtable manuscripts in Global Forum: Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation (September 2026) and Generating Label-Enabling Endpoint Data (October 2026).

Jul 2026 – Dec 2027
Phase II: Expansion and Implementation

Expanded to more than 60 experts from 11 member organizations. Phase II turns Phase I consensus into practical tools for endpoint measurement and multi-indication trial design, with continued engagement with FDA, EMA, and other global regulators.

Partners & Collaborators

Member Organizations

A diverse, global network of pharmaceutical and biotechnology leaders committed to improving the design, efficiency, and evidentiary value of obesity clinical trials.

AbbVie
Amgen
AstraZeneca
Boehringer Ingelheim
Eli Lilly
Genentech / Roche
IQVIA
Neurocrine Biosciences
Novo Nordisk
Pfizer
Regeneron
Governance & Leadership

Co-Chairs and Advisory Committee

The consortium draws on expertise and guidance from across industry, regulatory agencies, academia, medical experts, and patient advocacy organizations.

Co-Chairs

Working Group 1

  • Julia Luan, AstraZeneca
  • Alison Matsui, Genentech / Roche
  • Jenny Blau, Regeneron
  • Brad Jordan, Eli Lilly and Company

Working Group 2

  • Katherin Ruiz, Eli Lilly and Company
  • Jill Lee, Novo Nordisk
  • Kathleen Waldron, AbbVie
Advisory Committee
PC
Peggy Cawthon
Scientific Director
California Pacific Medical Center Research Institute
Joe Nadglowski
Joe Nadglowski
President / CEO
Obesity Action Coalition
TF
Teresa Fraker
Executive Director
Obesity Medicine Association
JB
Jennifer L. Baker
Head of Research, Lifecourse Epidemiology; President-Elect
EASO
BG
Bob Gabbay
Associate Professor of Medicine
Harvard Medical School
SH
Samar Hafida
Vice President, Obesity Association, American Diabetes Association; Assistant Professor of Medicine, Boston University Chobanian and Avedisian School of Medicine
Boston University / Boston Medical Center
IP
Ian Paton
Director of Advocacy and Public Engagement
Obesity Canada
FDA Participants
AT
Aliza Thompson, MD, MS
Division Director, OND / OCHEN / CDER
FDA / CDER
Jeffrey Siegel
Jeffrey Siegel, MD
Director, Office of Drug Evaluation Sciences
FDA / CDER
MR
Mark Rothmann, PhD
Director, Division of Biometrics II, Office of Biostatistics
FDA / CDER
RS
Ray Soccio, MD, PhD
Team Leader, Division of Diabetes, Lipid Disorders, and Obesity
FDA / CDER
Yoonhee Kim
Yoonhee Kim, PhD, MPH
Lead Mathematical Statistician, Diabetes Statistical Review Team, Division of Biometrics II, Office of Biostatistics
FDA / CDER
DIA Project Leadership
Maria Vassileva
Maria Vassileva
Chief Science and Regulatory Officer · Project Lead
DIA
Sorcha McCrohan
Sorcha McCrohan
Senior Scientific Project Manager · Provides all project management support across the team
DIA
Chris Gorini
Chris Gorini
Vice President, Global Science and Research Programs · Supports Working Group 2
DIA
Gregory Hustache
Gregory Hustache
Global Growth and Scientific Partnerships Leader · Contracts and Partnerships
DIA
✕
Joe Nadglowski
Joe Nadglowski
Obesity Action Coalition
President / CEO

Joe Nadglowski is President & CEO of the Obesity Action Coalition (OAC) – a nonprofit organization formed in 2005 dedicated to elevating and empowering individuals affected by obesity through education, advocacy and support. A frequent speaker and author, Mr. Nadglowski is especially passionate about access to obesity treatments, tackling weight bias and sharing his own experiences with obesity.

He has more than 25 years of experience working in patient advocacy, public policy and education and is a graduate of the University of Florida.

✕
Jeffrey Siegel
Jeffrey Siegel, MD
FDA / CDER
Director, Office of Drug Evaluation Sciences

Jeffrey Siegel is the Director of the Office of Drug Evaluation Sciences (ODES) in the Office of New Drugs (OND), CDER, FDA. ODES oversees Clinical Outcome Assessments, Biomarker Qualification, Research and Bioinformatics in OND. Dr. Siegel has over 20 years of experience in research, regulatory, and clinical drug development.

Jeff received his B.A. from Columbia University and M.D. from Yale University. Following his training in internal medicine and basic science research, he served at FDA from 1996–2010 as a medical officer and then Medical Team Leader. In 2010, he left FDA for industry and worked at Genentech/Roche and subsequently at Gilead Sciences before rejoining FDA in February 2021.

✕
Maria Vassileva
Maria Vassileva, Ph.D.
DIA
Chief Science and Regulatory Officer

Dr. Vassileva has decades of experience with managing complex multi-stakeholder biomedical research programs. She spent most of her career in the nonprofit sector, leading the Science Team at the Arthritis Foundation, and working at the Foundation for NIH and the American Association for the Advancement of Science. She was also on the leadership teams of two health research organizations, serving as project director on multiple government contracts.

Her areas of expertise include musculoskeletal, metabolic, immunity and inflammation disorders, as well as patient engagement. She received her PhD in Biochemistry and Cell Biology from Johns Hopkins.

✕
Sorcha McCrohan
Sorcha McCrohan
DIA
Senior Scientific Project Manager

Sorcha McCrohan is a Senior Scientific Project Manager for Global Science at DIA. In her current role, she focuses on content development and strategy for DIA's meetings to improve and facilitate innovation in clinical research, drug development, and the fields of devices and diagnostics.

Before joining DIA, she conducted COVID-19 research in Chiapas, Mexico, and worked in marketing within Pfizer's Global Vaccines franchise. Sorcha holds a BA in Sociology from Mount Holyoke College and an MSc in Global Health, Disease Prevention & Control from Georgetown University.

Impact & Outputs

Key Deliverables

The consortium generates practical, consensus-driven resources to inform obesity clinical development, regulatory engagement, and evidence-generation strategies worldwide. Phase I results are now published, and Phase II builds on them.

Core Clinical Endpoint Set

A consensus-based Core Clinical Endpoint Set to support standardized Phase 3 obesity trials across global regulatory regions.

Body Composition and Physical Function Standards

Recommendations on standardized approaches to measuring body composition and physical function as indicators of meaningful weight loss.

Multi-Indication Trial Design Frameworks

Frameworks for more efficient clinical trial designs, including master and basket protocols, that address obesity and priority comorbidities in a single development program.

White Papers and Publications

Two Executive Roundtable manuscripts published in Global Forum (Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation, September 2026, and Generating Label-Enabling Endpoint Data, October 2026), with more publications, presentations, and a webinar planned in Phase II.

How to Participate

Benefits of Membership

Participation is open to pharmaceutical and biotechnology companies, regulatory agencies, academic researchers, nonprofit organizations, patient advocacy groups, and other stakeholders engaged in obesity research and clinical development.

Early access to emerging frameworks and consensus recommendations for obesity clinical trial design and endpoints.
Direct collaboration with regulators, academic experts, patient advocates, and industry peers.
The opportunity to influence and shape evolving scientific, regulatory, and development practices in obesity.
Visibility and recognition through DIA publications, presentations, and events, including the DIA Global Annual Meeting and Executive Roundtables with regulators in the US and Europe.
Shared expertise and analyses that cut duplicated effort across sponsors.
Get Involved

Ready to Collaborate?

Organizations interested in contributing expertise, data, or strategic insight are invited to join Phase II through working groups, consortium meetings, and public-facing outputs.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。